<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092375</url>
  </required_header>
  <id_info>
    <org_study_id>B16-439</org_study_id>
    <nct_id>NCT03092375</nct_id>
  </id_info>
  <brief_title>Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects</brief_title>
  <official_title>A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment
      experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not
      complete the prescribed duration due to adverse event or any reason other than for non/poor
      compliance. Subjects will be randomized to 12 or 16 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to compare the efficacy and safety of glecaprevir and
      pibrentasvir (G/P) for 12 weeks to G/P for 16 weeks in non-cirrhotic NS5A (non-structural
      protein 5a)-inhibitor plus sofosbuvir ± RBV (Ribavirin) treatment-experienced adults with HCV
      genotype 1 (GT1) infection, and to compare the efficacy and safety of G/P with RBV for 12
      weeks to G/P without RBV for 16 weeks in NS5A-inhibitor plus sofosbuvir (SOF) ± RBV
      treatment-experienced adults with compensated cirrhosis and GT1 infection.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Up to 225 subjects will be enrolled into four study arms A, B, C and D containing Glecaprevir/Pibrentasvir (G/P) with or without Ribavirin (RBV).
Approximately 75-90 non-cirrhotic subjects will be randomized in a 2:1 ratio to Arms A and B, and approximately 110-135 subjects with compensated cirrhosis will be randomized in a 1:1 ratio to Arms C and D. Randomization will be stratified by HCV (Hepatitis C Virus) genotype 1 subtype (1b or non-1b).
Subjects without cirrhosis will be randomized 2:1 to:
Arm A: G/P 300 mg/120 mg QD (once a day) for 12 weeks
Arm B: G/P 300 mg/120mg QD for 16 weeks
Subjects with compensated cirrhosis will be randomized 1:1 to:
Arm C: G/P 300 mg/120 mg QD + weight-based RBV (Ribavirin) BID (twice a day) (1000 mg or 1200 mg total daily dose) for 12 weeks
Arm D: G/P 300 mg/120 mg QD for 16 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare percentage of non-cirrhotic participants achieving SVR 12 (Sustained Virologic Response at 12 weeks post treatment) after G/P 12 wks vs. G/P given for 16 weeks in non-cirrhotic tx-experienced GT1 HCV subjects</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Percentage of participants with undetectable HCV RNA 12 weeks after completing 12 or 16 weeks of G/P will be compared</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare percentage of cirrhotic participants achieving SVR 12 after G/P plus RBV for 12 wks vs. G/P for 16 Wks</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Percentage of participants with undetectable HCV RNA 12 weeks after completing 12 or 16 weeks of G/P will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in percentages of subjects with on-treatment virologic failure between 4 arms</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Percentage of subjects with detectable HCV RNA during treatment in Arm A will be compared to Arm B and Arm C will be compared to Arm D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in percentages of subjects with post-treatment relapse between arms</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Percentages of subjects with detectable HCV RNA following undetectable HCV RNA in Arm A vs. Arm B and Arm C vs. Arm D</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Arm A: G/P 300 mg/120 mg QD for 12 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-cirrhotic subjects will take 3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg tablets once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cirrhotic subjects will take 3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg tablets once-daily plus Ribavirin (RBV) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cirrhotic subjects will take 3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg tablets once-daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir (G/P) 300mg/120mg</intervention_name>
    <description>daily</description>
    <arm_group_label>Arm A: G/P 300 mg/120 mg QD for 12 Wks</arm_group_label>
    <arm_group_label>Arm B: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <arm_group_label>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</arm_group_label>
    <arm_group_label>Arm D: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <other_name>Glecaprevir/Pibrentasvir</other_name>
    <other_name>GLE/PIB (Glecaprevir/Pibrentasvir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin 200Mg Tablet</intervention_name>
    <description>Weight-based 1000-1200 mg</description>
    <arm_group_label>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</arm_group_label>
    <other_name>Ribasphere 200Mg Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 18 years of age at time of screening.

          2. A history of previous treatment with an NS5A-inhibitor plus sofosbuvir therapy ± RBV
             for chronic HCV genotype 1 infection.

          3. Treatment must have been completed at least 1 month prior to Screening Visit.

          4. Screening laboratory result indicating chronic HCV GT1 infection. Subjects must be
             able to understand and adhere to the study visit schedule and all other protocol
             requirements and must voluntarily sign and date an informed consent.

        Exclusion Criteria:

          1. History of severe, life-threatening or other significant sensitivity to any drug.

          2. Female who is pregnant, planning to become pregnant during the study or breastfeeding;
             or male whose partner is pregnant or planning to become pregnant during the study.

          3. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab) in patient without known history
             of HIV infection.

          5. HCV genotype performed during screening indicating co-infection with more than one HCV
             genotype.

          6. History or presence of liver decompensation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Jacksonville-Gastroenterology Emerson</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>303012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastro Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital/John G. Bartlett Specialty Practice</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates, PA</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Minnesota Health Clinics and Surgery Center, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Sandra Atlaas Bass Center for Liver Diseases</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine, Hepatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania-Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Previously treated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

